The majority of multiple myeloma patients relapse with the current treatment strategies, raising the need for alternative therapeutic approaches. Cellular immunotherapy is a rapidly evolving field and currently being translated into clinical trials with encouraging results in several cancer types, including multiple myeloma. Murine multiple myeloma models are of critical importance for the development and refinement of cellular immunotherapy. In this review,we summarize the immune cell changes that occur inmultiplemyelomapatients and we discuss the cell-based immunotherapies that have been tested in multiple myeloma, with a focus on murine models
Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incura...
\u3cp\u3eImmunotherapy holds promise for patients with multiple myeloma (MM), but little is known ab...
Multiple myeloma (MM) remains an incurable, genetically heterogeneous disease characterized by the u...
In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s ...
Multiple myeloma (MM) is usually diagnosed in older adults at the time of immunosenescence, a collec...
Multiple myeloma is an incurable disease of malignant plasma cells and an ideal target for modern im...
Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clona...
Multiple myeloma (MM) is a heterogeneous plasma cell malignancy differing substantially in clinical ...
Multiple myeloma (MM) is a tumor of terminally differentiated B cells that arises in the bone marrow...
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has...
Multiple myeloma (MM) remains an incurable hematological malignancy characterized by clonal prolifer...
The treatment of multiple myeloma (MM) has evolved substantially over the past decades, leading to a...
The power of immunotherapy in the battle of Multiple Myeloma (MM) started with allogeneic stem cell ...
Multiple myeloma (MM) is a life-threatening haematological malignancy for which standard therapy is ...
Multiple myeloma is an incurable plasma-cell malignancy characterized by osteolytic bone disease and...
Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incura...
\u3cp\u3eImmunotherapy holds promise for patients with multiple myeloma (MM), but little is known ab...
Multiple myeloma (MM) remains an incurable, genetically heterogeneous disease characterized by the u...
In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s ...
Multiple myeloma (MM) is usually diagnosed in older adults at the time of immunosenescence, a collec...
Multiple myeloma is an incurable disease of malignant plasma cells and an ideal target for modern im...
Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clona...
Multiple myeloma (MM) is a heterogeneous plasma cell malignancy differing substantially in clinical ...
Multiple myeloma (MM) is a tumor of terminally differentiated B cells that arises in the bone marrow...
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has...
Multiple myeloma (MM) remains an incurable hematological malignancy characterized by clonal prolifer...
The treatment of multiple myeloma (MM) has evolved substantially over the past decades, leading to a...
The power of immunotherapy in the battle of Multiple Myeloma (MM) started with allogeneic stem cell ...
Multiple myeloma (MM) is a life-threatening haematological malignancy for which standard therapy is ...
Multiple myeloma is an incurable plasma-cell malignancy characterized by osteolytic bone disease and...
Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incura...
\u3cp\u3eImmunotherapy holds promise for patients with multiple myeloma (MM), but little is known ab...
Multiple myeloma (MM) remains an incurable, genetically heterogeneous disease characterized by the u...